Clinical Scorecard: Management Strategies for Pediatric Patients with Adrenal Insufficiency
At a Glance
Category
Detail
Condition
Pediatric adrenal insufficiency including congenital adrenal hyperplasia (CAH) and central adrenal insufficiency (CAI)
Key Mechanisms
Deficient cortisol production due to adrenal or pituitary pathology; dysregulated androgen production in CAH
Target Population
Children and adolescents with primary or central adrenal insufficiency
Care Setting
Specialized pediatric endocrinology clinics and hospitals
Key Highlights
Goals of treatment include prevention of adrenal crises, optimization of growth, androgen control, and quality of life improvement.
Standard glucocorticoid therapy does not replicate physiological circadian cortisol rhythm; novel modified-release formulations and adjunctive therapies are emerging.
Diagnosis involves hormonal assays (ACTH, cortisol, 17OHP), genetic testing, and imaging (MRI) to define etiology and guide management.
Guideline-Based Recommendations
Diagnosis
Evaluate clinical signs such as ambiguous genitalia, vomiting, weight loss, premature pubarche, and hypoglycemia.
Perform hormonal testing including baseline and stimulated cortisol, ACTH, 17-hydroxyprogesterone, androstenedione, testosterone, and renin levels.
Use genetic analysis for confirmation of CAH (e.g., CYP21A2 mutations).
Conduct brain MRI to assess pituitary anatomy in suspected central adrenal insufficiency.
Management
Initiate prompt intravenous hydrocortisone and fluid resuscitation in salt-wasting crises.
Start glucocorticoid replacement therapy tailored to individual needs, considering modified-release hydrocortisone formulations to mimic circadian rhythm.
Use adjunctive therapies to reduce androgen production or action in CAH.
Treat associated hormone deficiencies (e.g., levothyroxine for central hypothyroidism) after initiating glucocorticoids.
Monitoring & Follow-up
Regular clinical assessment of growth parameters (height SDS, BMI SDS) using standardized charts.
Monitor hormonal levels (17OHP, testosterone, cortisol) to optimize dosing and control androgen excess.
Assess adherence and clinical symptoms including menstrual regularity and signs of adrenal crisis.
Follow-up imaging and biochemical tests as indicated.
Risks
Risk of life-threatening adrenal crises if untreated or undertreated.
Potential for growth impairment and androgen excess with suboptimal glucocorticoid dosing.
Adverse effects from overtreatment including Cushingoid features.
Complications from delayed diagnosis such as electrolyte imbalances and hypoglycemia.
Patient & Prescribing Data
Neonates, children, and adolescents diagnosed with classic or nonclassic CAH and central adrenal insufficiency
Hydrocortisone dosing individualized by age and severity; early initiation critical in salt-wasting crises; modified-release formulations and gene therapy under development to improve outcomes.
Clinical Best Practices
Prompt recognition and treatment of adrenal crises with intravenous hydrocortisone and electrolyte correction.
Use of genetic testing to confirm diagnosis and guide family counseling.
Tailoring glucocorticoid therapy to mimic physiological cortisol secretion and minimize androgen excess.
Comprehensive multidisciplinary follow-up including growth monitoring, hormonal assays, and imaging.
Addressing associated endocrine deficiencies in a coordinated manner.
